Myxinidin-Derived Peptide Against Biofilms Caused by Cystic Fibrosis Emerging Pathogens

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 25

PMID 36834512

Authors

Rosa Bellavita

Angela Maione

Simone Braccia

Marica Sinoca

Stefania Galdiero

Emilia Galdiero

Annarita Falanga

Affiliations

Soon will be listed here.

Abstract

Chronic lung infections in cystic fibrosis (CF) patients are triggered by multidrug-resistant bacteria such as , , and . The CF airways are considered ideal sites for the colonization and growth of bacteria and fungi that favor the formation of mixed biofilms that are difficult to treat. The inefficacy of traditional antibiotics reinforces the need to find novel molecules able to fight these chronic infections. Antimicrobial peptides (AMPs) represent a promising alternative for their antimicrobial, anti-inflammatory, and immunomodulatory activities. We developed a more serum-stable version of the peptide WMR (WMR-4) and investigated its ability to inhibit and eradicate , , and biofilms in both in vitro and in vivo studies. Our results suggest that the peptide is able better to inhibit than to eradicate both mono and dual-species biofilms, which is further confirmed by the downregulation of some genes involved in biofilm formation or in quorum-sensing signaling. Biophysical data help to elucidate its mode of action, showing a strong interaction of WMR-4 with lipopolysaccharide (LPS) and its insertion in liposomes mimicking Gram-negative and membranes. Our results support the promising therapeutic application of AMPs in the treatment of mono- and dual-species biofilms during chronic infections in CF patients.

Citing Articles

Antimicrobial Peptides: A Promising Alternative to Conventional Antimicrobials for Combating Polymicrobial Biofilms.

Roque-Borda C, Primo L, Medina-Alarcon K, Campos I, de Fatima Nascimento C, Saraiva M Adv Sci (Weinh). 2024; 12(1):e2410893.

PMID: 39530703 PMC: 11714181. DOI: 10.1002/advs.202410893.

"Stop, Little Pot" as the Motto of Suppressive Management of Various Microbial Consortia.

Efremenko E, Stepanov N, Senko O, Maslova O, Lyagin I, Domnin M Microorganisms. 2024; 12(8).

PMID: 39203492 PMC: 11356704. DOI: 10.3390/microorganisms12081650.

Strategic Single-Residue Substitution in the Antimicrobial Peptide Esc(1-21) Confers Activity against , Including Drug-Resistant and Biofilm Phenotype.

Loffredo M, Casciaro B, Bellavita R, Troiano C, Brancaccio D, Cappiello F ACS Infect Dis. 2024; 10(7):2403-2418.

PMID: 38848266 PMC: 11250030. DOI: 10.1021/acsinfecdis.4c00130.

Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.

Gourari-Bouzouina K, Boucherit-Otmani Z, Halla N, Seghir A, Baba Ahmed-Kazi Tani Z, Boucherit K Arch Microbiol. 2024; 206(6):255.

PMID: 38734793 DOI: 10.1007/s00203-024-03967-9.

A Re-Purposing Strategy: Sub-Lethal Concentrations of an Eicosanoid Derived from the Omega-3-Polyunsaturated Fatty Acid Resolvin D1 Affect Dual Species Biofilms.

Maione A, Buonanno A, Galdiero M, de Alteriis E, Petrillo F, Reibaldi M Int J Mol Sci. 2023; 24(16).

PMID: 37629056 PMC: 10454369. DOI: 10.3390/ijms241612876.

References

Hoyle N, Zhvaniya P, Balarjishvili N, Bolkvadze D, Nadareishvili L, Nizharadze D . Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res Microbiol. 2018; 169(9):540-542. DOI: 10.1016/j.resmic.2018.05.001. View

Kovacs R, Majoros L . Fungal Quorum-Sensing Molecules: A Review of Their Antifungal Effect against Biofilms. J Fungi (Basel). 2020; 6(3). PMC: 7559060. DOI: 10.3390/jof6030099. View

Yamaguchi H, Kodama H, Osada S, Kato F, Jelokhani-Niaraki M, Kondo M . Effect of alpha,alpha-dialkyl amino acids on the protease resistance of peptides. Biosci Biotechnol Biochem. 2003; 67(10):2269-72. DOI: 10.1271/bbb.67.2269. View

Dalcin D, Ulanova M . The Role of Human Beta-Defensin-2 in Pseudomonas aeruginosa Pulmonary Infection in Cystic Fibrosis Patients. Infect Dis Ther. 2014; 2(2):159-66. PMC: 4108104. DOI: 10.1007/s40121-013-0015-5. View

Scudiero O, Galdiero S, Nigro E, Del Vecchio L, Di Noto R, Cantisani M . Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines. Antimicrob Agents Chemother. 2013; 57(4):1701-8. PMC: 3623310. DOI: 10.1128/AAC.00934-12. View

de Kroon A, Soekarjo M, de Gier J, de Kruijff B . The role of charge and hydrophobicity in peptide-lipid interaction: a comparative study based on tryptophan fluorescence measurements combined with the use of aqueous and hydrophobic quenchers. Biochemistry. 1990; 29(36):8229-40. DOI: 10.1021/bi00488a006. View

Gallagher T, Phan J, Oliver A, Chase A, England W, Wandro S . Cystic Fibrosis-Associated Stenotrophomonas maltophilia Strain-Specific Adaptations and Responses to pH. J Bacteriol. 2019; 201(7). PMC: 6416904. DOI: 10.1128/JB.00478-18. View

Allan K, Farrow N, Donnelley M, Jaffe A, Waters S . Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies. Front Pharmacol. 2021; 12:639475. PMC: 8007963. DOI: 10.3389/fphar.2021.639475. View

Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I . Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007; 115(8):891-9. DOI: 10.1111/j.1600-0463.2007.apm_630.x. View

10.

Pfaffl M, Horgan G, Dempfle L . Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30(9):e36. PMC: 113859. DOI: 10.1093/nar/30.9.e36. View

11.

Chotirmall S, ODonoghue E, Bennett K, Gunaratnam C, ONeill S, McElvaney N . Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis. Chest. 2010; 138(5):1186-95. DOI: 10.1378/chest.09-2996. View

12.

Goss C, Mayer-Hamblett N, Aitken M, Rubenfeld G, Ramsey B . Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax. 2004; 59(11):955-9. PMC: 1746887. DOI: 10.1136/thx.2003.017707. View

13.

Ben Hur D, Kapach G, Wani N, Kiper E, Ashkenazi M, Smollan G . Antimicrobial Peptides against Multidrug-Resistant Biofilm from Cystic Fibrosis Patients. J Med Chem. 2022; 65(13):9050-9062. PMC: 9289885. DOI: 10.1021/acs.jmedchem.2c00270. View

14.

Yousif A, Ingangi V, Merlino F, Brancaccio D, Minopoli M, Bellavita R . Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration. Eur J Med Chem. 2017; 143:348-360. DOI: 10.1016/j.ejmech.2017.11.030. View

15.

Sherrard L, Tunney M, Elborn J . Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet. 2014; 384(9944):703-13. DOI: 10.1016/S0140-6736(14)61137-5. View

16.

Sinha S, Zheng L, Mu Y, Ng W, Bhattacharjya S . Structure and Interactions of A Host Defense Antimicrobial Peptide Thanatin in Lipopolysaccharide Micelles Reveal Mechanism of Bacterial Cell Agglutination. Sci Rep. 2017; 7(1):17795. PMC: 5736615. DOI: 10.1038/s41598-017-18102-6. View

17.

Keown K, Reid A, Moore J, Taggart C, Downey D . Coinfection with and in cystic fibrosis. Eur Respir Rev. 2020; 29(158). PMC: 9489137. DOI: 10.1183/16000617.0011-2020. View

18.

Ronald P . Small protein-mediated quorum sensing in a gram-negative bacterium: novel targets for control of infectious disease. Discov Med. 2011; 12(67):461-70. View

19.

Jennings L, Dreifus J, Reichhardt C, Storek K, Secor P, Wozniak D . Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies. Cell Rep. 2021; 34(8):108782. PMC: 7958924. DOI: 10.1016/j.celrep.2021.108782. View

20.

Gade S, Norskov-Lauritsen N, Ridderberg W . Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. J Med Microbiol. 2017; 66(5):686-689. DOI: 10.1099/jmm.0.000499. View